Tenax Therapeutics, Inc.

Equities

TENX

US88032L6056

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
4.24 USD +9.56% Intraday chart for Tenax Therapeutics, Inc. +8.16% -80.70%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tenax Therapeutics Secures Global Rights for Levosimendan MT
Tenax Therapeutics, Inc. and Orion Corporation Enters into an Amendment to Certain License Agreement CI
Top Midday Decliners MT
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Investors Await Economic Data MT
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data MT
Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients CI
Sector Update: Health Care Stocks Gain Late Afternoon MT
Sector Update: Health Care MT
Top Midday Gainers MT
Tenax Therapeutics, Inc. Appoints Lawrence R. Hoffman as Principal Financial Officer and Principal Accounting Officer CI
Tenax Therapeutics, Inc. Announces Chief Financial Officer Changes CI
Tenax Therapeutics to Implement 1-for-80 Reverse Stock Split MT
Tenax Therapeutics, Inc. Appoints Javed Butler to its PH-HFpEF Scientific Advisory Board CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sector Update: Health Care Stocks Gain in Late Afternoon Trading MT
Sector Update: Health Care MT
Top Midday Gainers MT
Tenax Therapeutics Shares Double Premarket After FDA Clears IND for TNX-103 DJ
Tenax Therapeutics, Inc. Announces FDA Clearance of IND for TNX-103 for the Treatment of Pulmonary Hypertension with Heart Failure CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Tenax Therapeutics Issues U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) CI
Tenax Therapeutics, Inc. Receives a Notice of Allowance from the United States Patent and Trademark Office for its Patent Application CI
Tenax Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart Tenax Therapeutics, Inc.
More charts
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). It has the rights to develop and commercialize IV (TNX-101), subcutaneous (TNX-102), and oral (TNX-103) formulations of levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
4.24 USD
Average target price
32.5 USD
Spread / Average Target
+666.51%
Consensus
  1. Stock
  2. Equities
  3. Stock Tenax Therapeutics, Inc. - Nasdaq
  4. News Tenax Therapeutics, Inc.
  5. Tenax Therapeutics : Directors Blanck, Pepin, and Rallis Won't Seek Re-Election to Board